Want to see PRME full AI Analyst Report?
PRME Stock Chart & Stats
$3.81
-$0.14(-4.27%)
At close: 4:00 PM EST
$3.81
-$0.14(-4.27%)
Day’s Range― - ―
52-Week Range$2.67 - $6.94
Previous CloseN/A
Volume144.88K
Average Volume (3M)3.84M
Market Cap
$581.59M
Enterprise Value$621.16M
Total Cash (Recent Filing)$135.50M
Total Debt (Recent Filing)$114.51M
Price to Earnings (P/E)―
Beta2.86
Next Earnings
Aug 06, 2026EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.27
Shares Outstanding180,617,450
10 Day Avg. Volume4,671,386
30 Day Avg. Volume3,843,301
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)4.27
Price to Sales (P/S)111.44
P/FCF Ratio-3.09
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue153.98
Enterprise Value/Gross Profit-14.22
Enterprise Value/Ebitda-3.25
Forecast
1Y Price Target
$7.83Price Target Upside105.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-1
Revenue Forecast (FY)$12.18M
Bulls Say, Bears Say
Bulls Say
Prime Editing PlatformPrime's proprietary Prime Editing platform is a durable strategic asset: it supports a broad pipeline of gene-editing candidates, can underpin multiple future programs and partnerships, and creates long-term optionality for licensing, collaborations, and platform-driven revenue streams.
Arbitration Clarifies PM647 RightsThe arbitration award removes a material legal overhang and secures Prime’s development rights for PM647, preserving program value, reducing risk for partners and investors, and enabling uninterrupted development and commercialization planning over the medium term.
Governance & Shareholder SupportShareholder reaffirmation of board members and auditor indicates governance stability and continuity. Stable governance reduces execution risk for clinical programs, supports consistent oversight, and helps with credibility when negotiating partnerships or raising capital.
Bears Say
Persistent UnprofitabilityLarge, sustained operating losses relative to a small revenue base weaken return generation and erode equity over time. Continued unprofitability increases dependence on external financing and can limit resources available to advance multiple programs or scale operations.
High Cash BurnConsistent negative operating and free cash flow depletes cash reserves and forces reliance on dilutive equity or debt financing. Persistent burn constrains long-term program funding, increases refinancing risk, and can force prioritization or delay of clinical development activities.
Rising LeverageMaterial increase in debt and higher leverage reduce financial flexibility and raise fixed obligations. Elevated leverage amplifies refinancing and covenant risk, limits capacity to fund R&D organically, and makes the company more vulnerable to adverse market or clinical setbacks.
Prime Medicine, Inc. News
PRME FAQ
What was Prime Medicine, Inc.’s price range in the past 12 months?
Prime Medicine, Inc. lowest stock price was $2.67 and its highest was $6.94 in the past 12 months.
What is Prime Medicine, Inc.’s market cap?
Prime Medicine, Inc.’s market cap is $581.59M.
When is Prime Medicine, Inc.’s upcoming earnings report date?
Prime Medicine, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 18 days.
How were Prime Medicine, Inc.’s earnings last quarter?
Prime Medicine, Inc. released its earnings results on May 07, 2026. The company reported -$0.28 earnings per share for the quarter, missing the consensus estimate of -$0.251 by -$0.029.
Is Prime Medicine, Inc. overvalued?
According to Wall Street analysts Prime Medicine, Inc.’s price is currently Undervalued.
Does Prime Medicine, Inc. pay dividends?
Prime Medicine, Inc. pays a Quarterly dividend of $0.8 which represents an annual dividend yield of N/A. See more information on Prime Medicine, Inc. dividends here
What is Prime Medicine, Inc.’s EPS estimate?
Prime Medicine, Inc.’s EPS estimate is -0.26.
How many shares outstanding does Prime Medicine, Inc. have?
Prime Medicine, Inc. has 180,617,450 shares outstanding.
What happened to Prime Medicine, Inc.’s price movement after its last earnings report?
Prime Medicine, Inc. reported an EPS of -$0.28 in its last earnings report, missing expectations of -$0.251. Following the earnings report the stock price went down -8.651%.
Which hedge fund is a major shareholder of Prime Medicine, Inc.?
Currently, no hedge funds are holding shares in PRME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prime Medicine, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.83 (105.60% Upside)
$7.83 (105.60% Upside)
Blogger Sentiment
Bullish
PRME Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 780.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.0%
Last 30 Days ▲ 17.2%
Last 30 Days ▲ 17.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-20.29%
12-Months-Change
Fundamentals
Return on Equity
-188.82%
Trailing 12-Months
Asset Growth
-10.19%
Trailing 12-Months
Company Description
Prime Medicine, Inc.
Prime Medicine, Inc. operates as a biotechnology firm, dedicated to delivering genetic therapies for various diseases by strategically employing advanced gene editing technology. Central to their platform is the "Prime Editor" system, which combines a unique Prime Editor protein—a hybrid composed of a Cas protein and a reverse transcriptase enzyme—with a specialized pegRNA molecule. This pegRNA plays a crucial role by both guiding the Prime Editor to a precise location within the genome and providing the essential template for introducing the desired modification to the target DNA sequence. The company, founded in 2019, maintains its headquarters in Cambridge, Massachusetts.
PRME Stock 12 Month Forecast
Average Price Target
$7.83
▲(105.60% Upside)
Technical Analysis
Immatics
―
Relay Therapeutics
―
Taysha Gene Therapies
―
Sana Biotechnology
―
Upstream Bio, Inc.
―
Ownership Overview
35.58% Insiders
7.24% Mutual Funds
0.20% Other Institutional Investors
43.10% Public Companies and
Individual Investors